Enhanced Risk Stratification in Stage I Melanoma Patients Using DecisionDx-Melanoma Overview Company: Castle Biosciences, Inc. Indication: Stage I Cutaneous Melanoma (CM) Drug/test: DecisionDx-Melanoma Test Trial Phase: Not Applicable NCT ID: Not Available Background Castle Biosciences, Inc. announced on February 26, 2024, a significant enhancement in risk stratification for Stage I Cutaneous Me..
Preliminary Results Display Full Tumor Eradication in Non-surgical Breast Cancer Patients Using IceCure's ProSense® Cryoablation Therapy Overview Company: IceCure Medical Ltd. Indication: Early-Stage Breast Cancer Drug/Treatment: ProSense® System Trial Phase: Not applicable NCT ID: Not available Study Summary In a groundbreaking study led by Dr. Federica di Naro at Azienda Ospedaliero-Universita..
NewBiologix Engages with Florabio to Transform Gene Therapy Manufacturing through Advanced HEK293 Cell Line Engineering Company: NewBiologix SA Indication: Not Applicable Drug: Recombinant adeno-associated virus (rAAV) vectors Trial Phase: Not Applicable NCT ID: Not Available Overview On February 27, 2024, NewBiologix SA, a biotech firm based in Lausanne, Switzerland, announced a strategic partn..
Bitterroot Bio and Biotheus Forge Partnership for Bispecific Protein Development in Cardiovascular Immunotherapy Overview Company: Bitterroot Bio; Biotheus Indication: Cardiovascular diseases Drug: N/A Trial Phase: N/A NCT ID: N/A Details In a significant stride within the field of cardio-immunology, Bitterroot Bio and Biotheus have publicly announced the establishment of a multi-year research c..
Third Pole Therapeutics Triumphs with eNOfit™ System EFS for Non-Hospital Treatment of Pulmonary Hypertension Overview Company: Third Pole Therapeutics Indication: Pulmonary hypertension associated with Interstitial Lung Disease (ILD) Drug: eNOfit™ (Inhaled Nitric Oxide Delivery System) Trial Phase: N/A NCT ID: Not available Early Feasibility Study (EFS) Success Third Pole Therapeutics, a forefr..
Baseimmune Secures $11.3 Million Series A Investment for Accelerated Development of AI-Designed Cross-Protective Vaccines Company: Baseimmune Indication: - African swine fever - Coronavirus - Malaria Drug: AI-designed cross-protective vaccine candidates Trial Phase: N/A NCT ID: N/A Overview Baseimmune is a biotechnological firm committed to leading vaccine innovation using a proprietary artifici..
Hoth Therapeutics Advances Preclinical Development of HT-KIT With Altasciences Collaboration for Mast Cell-Derived Cancer Treatment Overview Company: Hoth Therapeutics, Inc. Indication: Mast Cell-Derived Cancers Drug: HT-KIT Trial Phase: Preclinical (N/A for IND-enabling studies) Nct ID: Not applicable Development Update Hoth Therapeutics, Inc., a patient-focused biopharmaceutical company, has a..